F4 Pharma

Executive Summary

F4 Pharma GmbH is a development-stage biopharmaceutical company based in Vienna, Austria, founded in 2020. The company focuses on converting high-impact scientific discoveries into treatments for orphan diseases, particularly capillary leak syndrome and inflammation. Its lead asset, FX06, is a peptide designed to inhibit acute inflammatory reactions and prevent vascular leakage through a novel mechanism of action. F4 Pharma addresses significant unmet medical needs by targeting conditions with limited therapeutic options. The company operates in the oncology and small molecules categories, leveraging a proprietary platform to develop its pipeline. Although still in early clinical stages, FX06 has shown promise in preclinical models, positioning the company as a potential player in the orphan disease space. F4 Pharma is privately held and has not disclosed funding details or valuation.

Upcoming Catalysts (preview)

• Q3 2026Initiation of Phase 2 trial for FX06 in capillary leak syndrome65% success
• Q4 2026Release of preclinical data for FX06 in additional inflammatory indications50% success